Antibody-mediated Rejection Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024-2034), | DelveInsight | CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, Farsad Eskandary, CSL Behring, Bristol-Myers Squibb

DelveInsight's "Antibody-mediated Rejection Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Antibody-mediated Rejection, historical and forecasted epidemiology as well as the Antibody-mediated Rejection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Antibody-mediated Rejection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Antibody-mediated Rejection Market Forecast
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Antibody-mediated Rejection Market Report:
• The Antibody-mediated Rejection market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• The market size for antibody-mediated rejection was largest in the United States, amounting to around USD 70 million, surpassing that of EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• In March 2024, Human Immunology Biosciences (HI-Bio™), a biotech firm in the clinical stage, specializing in tailored treatments for individuals grappling with severe immune-mediated disorders (IMDs), has revealed that the U.S. Food and Drug Administration (FDA) has conferred Orphan Drug Designation (ODD) upon felzartamab. This designation is specifically for addressing antibody-mediated rejection (AMR) in recipients of kidney transplants.
• The incidence of Antibody-mediated Rejection in kidney transplants was highest in the United States. According to DelveInsight's predictions, the number of kidney transplants performed nationwide in 2019 was 1,887; this number is projected to rise to 2,032 by 2032
• France had the most antibody-mediated rejection (AMR) instances among the European nations in 2019 with 459 cases, followed by Spain with 419 cases. Germany, on the other side, had the lowest number in 2019, with 259 cases
• Key Antibody-mediated Rejection Companies: CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, Farsad Eskandary, Bristol-Myers Squibb, Janssen, LP, Alexion, and others
• Key Antibody-mediated Rejection Therapies: Clazakizumab, Imlifidase, VIB4920 (HZN-4920), Felzartamab, Physiologic saline solution, Belatacept, Daratumumab, BIVV020 (SAR445088), Nulojix (Belatacept), Eculizumab, and others
• The Antibody-mediated Rejection epidemiology based on gender analyzed that both males and females are affected equally by Antibody-mediated Rejection
• The Antibody-mediated Rejection market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Antibody-mediated Rejection pipeline products will significantly revolutionize the Antibody-mediated Rejection market dynamics.

Antibody-mediated Rejection Overview
Antibody-mediated rejection (AMR) is a serious complication that can occur after organ transplantation, particularly kidney transplantation. It results from the recipient's immune system producing antibodies that attack the transplanted organ. This immune response is typically directed against the donor organ's antigens, which are perceived as foreign by the recipient's immune system.

Get a Free sample for the Antibody-mediated Rejection Market Report:
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Antibody-mediated Rejection Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Antibody-mediated Rejection Epidemiology Segmentation:
The Antibody-mediated Rejection market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Antibody-mediated Rejection
• Prevalent Cases of Antibody-mediated Rejection by severity
• Gender-specific Prevalence of Antibody-mediated Rejection
• Diagnosed Cases of Episodic and Chronic Antibody-mediated Rejection

Download the report to understand which factors are driving Antibody-mediated Rejection epidemiology trends @ Antibody-mediated Rejection Epidemiology Forecast
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Antibody-mediated Rejection Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Antibody-mediated Rejection market or expected to get launched during the study period. The analysis covers Antibody-mediated Rejection market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Antibody-mediated Rejection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Antibody-mediated Rejection Therapies and Key Companies
• Clazakizumab: CSL Behring
• Imlifidase: Hansa Biopharma
• VIB4920 (HZN-4920): Horizon Therapeutics
• Felzartamab: Farsad Eskandary
• Physiologic saline solution: CSL Behring
• Belatacept: Bristol-Myers Squibb
• Daratumumab: Janssen, LP
• BIVV020 (SAR445088): Sanofi
• Nulojix (Belatacept): Bristol-Myers Squibb
• Eculizumab: Alexion

Discover more about therapies set to grab major Antibody-mediated Rejection market share @ Antibody-mediated Rejection Treatment Market
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Antibody-mediated Rejection Market Drivers
• Emerging Therapy
• Development of Personalized Therapy
• Targeting of Novel Pathways
• Increased Rate of Organ Donation
• Development of Gene therapy

Antibody-mediated Rejection Market Barriers
• Challenges in Designing Clinical Trials
• Need for Evidence-based Treatment Guidelines
• High Clinical Burden

Scope of the Antibody-mediated Rejection Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Antibody-mediated Rejection Companies: CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, Farsad Eskandary, Bristol-Myers Squibb, Janssen, LP, Alexion, and others
• Key Antibody-mediated Rejection Therapies: Clazakizumab, Imlifidase, VIB4920 (HZN-4920), Felzartamab, Physiologic saline solution, Belatacept, Daratumumab, BIVV020 (SAR445088), Nulojix (Belatacept), Eculizumab, and others
• Antibody-mediated Rejection Therapeutic Assessment: Antibody-mediated Rejection current marketed and Antibody-mediated Rejection emerging therapies
• Antibody-mediated Rejection Market Dynamics: Antibody-mediated Rejection market drivers and Antibody-mediated Rejection market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Antibody-mediated Rejection Unmet Needs, KOL's views, Analyst's views, Antibody-mediated Rejection Market Access and Reimbursement

To know more about Antibody-mediated Rejection companies working in the treatment market, visit @ Antibody-mediated Rejection Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Antibody-mediated Rejection Market Report Introduction
2. Executive Summary for Antibody-mediated Rejection
3. SWOT analysis of Antibody-mediated Rejection
4. Antibody-mediated Rejection Patient Share (%) Overview at a Glance
5. Antibody-mediated Rejection Market Overview at a Glance
6. Antibody-mediated Rejection Disease Background and Overview
7. Antibody-mediated Rejection Epidemiology and Patient Population
8. Country-Specific Patient Population of Antibody-mediated Rejection
9. Antibody-mediated Rejection Current Treatment and Medical Practices
10. Antibody-mediated Rejection Unmet Needs
11. Antibody-mediated Rejection Emerging Therapies
12. Antibody-mediated Rejection Market Outlook
13. Country-Wise Antibody-mediated Rejection Market Analysis (2020-2034)
14. Antibody-mediated Rejection Market Access and Reimbursement of Therapies
15. Antibody-mediated Rejection Market Drivers
16. Antibody-mediated Rejection Market Barriers
17. Antibody-mediated Rejection Appendix
18. Antibody-mediated Rejection Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Antibody-mediated Rejection Epidemiology https://www.delveinsight.com/report-store/antibody-mediated-rejection-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Antibody-mediated Rejection Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Antibody-mediated Rejection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Orthopedic Trauma Devices Market https://www.delveinsight.com/report-store/orthopedic-trauma-devices-market
Global Orthopedic Trauma Devices Market was valued at USD 7.01 billion in 2023, growing at a CAGR of 6.43% during the forecast period from 2024 to 2030 to reach USD 10.15 billion by 2030. The demand for orthopedic trauma devices is witnessing growth due to the rising number of accident and trauma cases, growing prevalence of degenerative bone disorders, the rising number of sports-related injuries, rising demand for technologically advanced products, and increasing geriatric population are expected to drive product demand in the global orthopedic trauma devices market.

Acute Ischemic Stroke Market
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
DelveInsight's 'Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of acute ischemic stroke in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Advanced Wound Care Market
https://www.delveinsight.com/report-store/advanced-wound-care-market
As per DelveInsight, the global Advanced Wound Care Market was valued at USD 10.44 billion in 2023, growing at a CAGR of 10.82% during the forecast period from 2024 to 2030, to reach USD 19.29 billion by 2030. The demand for advanced wound care is predominantly associated with the rising incidence of chronic wounds associated with various chronic disorders such as diabetes, and cancer, and also with the rising incidence of active wounds comprising burns, and surgical wounds, among others

Alcohol Use Disorder Market
https://www.delveinsight.com/report-store/alcohol-use-disorder-market
DelveInsight's "Alcohol Use Disorder (AUD) Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of AUD, historical and forecasted epidemiology, as well as the AUD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Congestive Heart Failure Market
https://www.delveinsight.com/report-store/congestive-heart-failure-market
DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CHF, historical and forecasted epidemiology as well as the CHF market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

CDMO Market
https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market
Global CDMO market was valued at USD 100.02 billion in 2021, growing at a CAGR of 6.25% during the forecast period from 2024 to 2030, in order to reach USD 143.87 billion by 2030. Factors such as rising prevalence of various chronic and acute diseases leading to growing requirement of drugs, rising popularity of biologics as a treatment option are further expected to drive the demand for services offered by CDMOs as biologics being more complex than small molecules require elaborate facilities for product development.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.